See more : Technology One Limited (TNE.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Polarean Imaging plc (PLLWF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Polarean Imaging plc, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- James Halstead plc (JHD.L) Income Statement Analysis – Financial Results
- Sabina Public Company Limited (SABINA-R.BK) Income Statement Analysis – Financial Results
- Lithium Plus Minerals Ltd (LPM.AX) Income Statement Analysis – Financial Results
- Halfords Group plc (HLFDF) Income Statement Analysis – Financial Results
- Electronic Servitor Publication Network, Inc. (XESP) Income Statement Analysis – Financial Results
Polarean Imaging plc (PLLWF)
About Polarean Imaging plc
Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, Germany, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 890.93K | 1.03M | 1.19M | 1.06M | 2.30M | 2.44M | 1.24M | 880.65K | 902.34K | 965.43K |
| Cost of Revenue | 555.45K | 684.73K | 677.40K | 346.30K | 925.61K | 633.46K | 297.22K | 488.89K | 308.56K | 168.03K |
| Gross Profit | 335.48K | 348.28K | 508.03K | 710.47K | 1.38M | 1.81M | 939.95K | 391.76K | 593.78K | 797.40K |
| Gross Profit Ratio | 37.66% | 33.71% | 42.86% | 67.23% | 59.78% | 74.03% | 75.98% | 44.49% | 65.80% | 82.60% |
| Research & Development | 4.19M | 607.76K | 638.59K | 480.89K | 161.31K | 642.46K | 176.11K | 145.44K | 162.98K | 269.83K |
| General & Administrative | 3.34M | 8.46M | 6.52M | 5.05M | 6.01M | 6.16M | 4.05M | 1.28M | 1.19M | 769.96K |
| Selling & Marketing | 3.56M | 3.31M | 5.56M | 917.78K | 324.79K | 31.77K | 28.75K | 35.24K | 25.39K | 86.41K |
| SG&A | 6.90M | 11.78M | 12.08M | 5.97M | 6.33M | 6.19M | 4.08M | 1.32M | 1.21M | 856.37K |
| Other Expenses | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.89M | 14.02M | 14.82M | 7.33M | 7.39M | 7.07M | 4.86M | 1.45M | 1.51M | 869.11K |
| Cost & Expenses | 13.45M | 14.70M | 15.50M | 7.67M | 8.31M | 7.71M | 5.16M | 1.94M | 1.81M | 1.04M |
| Interest Income | 759.00 | 35.05K | 2.59K | 100.77K | 508.00 | 184.00 | 129.00 | 147.00 | 159.31K | 37.69K |
| Interest Expense | 15.99K | 23.76K | 20.74K | 19.73K | 91.68K | 188.06K | 34.06K | 4.32K | 0.00 | 0.00 |
| Depreciation & Amortization | 959.78K | 1.02M | 918.40K | 942.62K | 775.69K | 598.87K | 387.84K | 9.35K | 9.99K | 12.74K |
| EBITDA | -11.19M | -12.78M | -13.38M | -5.73M | -5.26M | -4.64M | -3.55M | -1.05M | -617.40K | -58.97K |
| EBITDA Ratio | -1,256.55% | -1,243.32% | -1,128.88% | -532.81% | -228.79% | -190.22% | -287.32% | -118.80% | -68.42% | -6.11% |
| Operating Income | -12.56M | -13.67M | -14.32M | -6.62M | -6.01M | -5.27M | -3.92M | -1.06M | -627.39K | -71.71K |
| Operating Income Ratio | -1,409.33% | -1,323.38% | -1,207.70% | -626.02% | -261.27% | -215.93% | -317.17% | -119.86% | -69.53% | -7.43% |
| Total Other Income/Expenses | 671.36K | -235.03K | 300.44K | 81.04K | -91.17K | -187.87K | -33.93K | -4.17K | -159.31K | -37.69K |
| Income Before Tax | -11.88M | -13.91M | -14.02M | -6.53M | -6.10M | -5.45M | -3.96M | -1.06M | -1.07M | -109.40K |
| Income Before Tax Ratio | -1,333.97% | -1,346.13% | -1,182.36% | -618.35% | -265.24% | -223.63% | -319.91% | -120.33% | -118.66% | -11.33% |
| Income Tax Expense | 0.00 | -211.26K | 1.00 | 100.77K | 508.00 | 465.85K | -18.62K | 0.00 | 0.00 | 0.00 |
| Net Income | -11.88M | -13.91M | -14.02M | -6.53M | -6.10M | -5.45M | -3.96M | -1.06M | -1.07M | -109.40K |
| Net Income Ratio | -1,333.97% | -1,346.13% | -1,182.36% | -618.35% | -265.24% | -223.63% | -319.91% | -120.33% | -118.66% | -11.33% |
| EPS | -0.06 | -0.07 | -0.07 | -0.04 | -0.06 | -0.08 | -0.14 | -0.99 | -1.49 | -0.17 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.04 | -0.06 | -0.08 | -0.14 | -0.99 | -1.49 | -0.17 |
| Weighted Avg Shares Out | 214.28M | 211.95M | 196.96M | 150.21M | 107.20M | 69.94M | 28.46M | 1.07M | 717.11K | 627.93K |
| Weighted Avg Shares Out (Dil) | 214.28M | 211.95M | 196.96M | 150.21M | 107.20M | 69.94M | 28.46M | 1.07M | 717.11K | 627.92K |
Polarean Imaging's CEO discusses new partnership and growth strategies
In a recent interview with Thomas Warner from Proactive, Christopher von Jako, CEO of Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), shared exciting developments following the announcement of the company's first de novo order for its cutting-edge XENOVIEW polariser. Von Jako, who...
Polarean Imaging hails new polariser order from top US academic medical unit
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) hailed the receipt its first de novo order for its XENOVIEW polariser from a top-tier academic medical centre, in the US north-east. The company, which added that its current cash runway is expected to last...
Polarean Imaging partners up to enhance potential of Xenon 129 MRI technology
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) (AIM: POLX), a specialist in advanced magnetic resonance imaging (MRI) for the lungs, has announced a strategic partnership with VIDA Diagnostics, a clinical imaging intelligence firm. The collaboration aims to enhance the Polarean xenon 129...
Polarean Imaging new CEO sets out new sales initiatives, extends cash runway
New Polarean Imaging PLC chief executive Christopher von Jako said he has identified five growth initiatives that also extend the group's cash runway out to the middle of next year. The advanced lung MRI scanning specialist reported results for the...
Plarean Imaging says Medicare code in line with expectations
Polarean Imaging said it has been issued a US reimbursement code for its XENOVIEW lung imaging technology that corresponds to a payment range of between $1,201 to $1,300 as part of the 2023 Medicare Hospital Outpatient regime. “The codes enable healthcare providers...
Polarean Imaging up 8% as US grant reimbursement code
Polarean Imaging rose 8% as the US granted it a crucial reimbursement code, meaning its technology can be used in private and public healthcare programmes.
Polarean Imaging MRI technology granted billing code for healthcare providers
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF)'s magnetic resource imaging (MRI) contrasting agent has been granted a reimbursement code in the United States, meaning healthcare providers can bill following use of the technology. The code “C9791” can be used for healthcare providers...
Polarean hits another key milestone with University of Missouri upgrade
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), a leader in advanced lung MRI scanning, has upgraded the University of Missouri Health Care (MU Health Care) Department of Radiology's polariser system for clinical use. The conversion marks a key milestone in the execution...
Polarean Imaging appoints new CEO as Hullihen prepares to retire
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has appointed Christopher von Jako as its new chief executive. Effective immediately, von Jako takes over from Richard Hullihen, who is retiring but will remain in a transitional role for six months.
Polarean Imaging and electrical giant Phillps in lung imaging collaboration
Polarean Imaging said it has entered into a collaboration with Dutch electrical giant Philips to advance the field of hyperpolarised Xenon MRI. Philips will showcase its 3T MR 7700 system featuring Polarean's XENOVIEW (xenon Xe 129 hyperpolarised) technology at August's International Society...
Source: https://incomestatements.info
Category: Stock Reports